Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia

Essential thrombocythaemia (ET) is a rare myeloproliferative neoplasm. This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagrelide or hydroxyurea in high-risk ET patients for up to 3 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotic, Mirjana, Egyed, Miklos, Gercheva, Liana, Warzocha, Krzysztof, Kvasnicka, Hans Michael, Achenbach, Heinrich, Wu, Jingyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847982/
https://www.ncbi.nlm.nih.gov/pubmed/33123978
http://dx.doi.org/10.1007/s12012-020-09615-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847982/
https://www.ncbi.nlm.nih.gov/pubmed/33123978
http://dx.doi.org/10.1007/s12012-020-09615-0

Ejemplares similares